vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Koppers Holdings Inc. (KOP). Click either name above to swap in a different company.
Koppers Holdings Inc. is the larger business by last-quarter revenue ($432.7M vs $247.1M, roughly 1.8× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 6.9%, a 4.3% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs -9.3%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $28.5M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs -6.7%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Koppers is a global chemical and materials company based in Pittsburgh, Pennsylvania, United States. Its headquarters is an art-deco 1920s skyscraper, the Koppers Tower.
ANIP vs KOP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $432.7M |
| Net Profit | $27.5M | $29.7M |
| Gross Margin | — | 25.6% |
| Operating Margin | 14.1% | 11.5% |
| Net Margin | 11.1% | 6.9% |
| Revenue YoY | 29.6% | -9.3% |
| Net Profit YoY | 367.5% | 391.2% |
| EPS (diluted) | $1.14 | $1.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $432.7M | ||
| Q3 25 | $227.8M | $485.3M | ||
| Q2 25 | $211.4M | $504.8M | ||
| Q1 25 | $197.1M | $456.5M | ||
| Q4 24 | $190.6M | $477.0M | ||
| Q3 24 | $148.3M | $554.3M | ||
| Q2 24 | $138.0M | $563.2M | ||
| Q1 24 | $137.4M | $497.6M |
| Q4 25 | $27.5M | $29.7M | ||
| Q3 25 | $26.6M | $23.8M | ||
| Q2 25 | $8.5M | $16.4M | ||
| Q1 25 | $15.7M | $-13.9M | ||
| Q4 24 | $-10.3M | $-10.2M | ||
| Q3 24 | $-24.2M | $22.8M | ||
| Q2 24 | $-2.3M | $26.8M | ||
| Q1 24 | $18.2M | $13.0M |
| Q4 25 | — | 25.6% | ||
| Q3 25 | — | 24.1% | ||
| Q2 25 | — | 22.6% | ||
| Q1 25 | — | 23.2% | ||
| Q4 24 | — | 17.5% | ||
| Q3 24 | — | 21.9% | ||
| Q2 24 | — | 21.6% | ||
| Q1 24 | — | 19.3% |
| Q4 25 | 14.1% | 11.5% | ||
| Q3 25 | 15.9% | 10.7% | ||
| Q2 25 | 6.6% | 7.7% | ||
| Q1 25 | 13.3% | 5.9% | ||
| Q4 24 | -2.3% | 1.3% | ||
| Q3 24 | -13.8% | 9.0% | ||
| Q2 24 | 3.7% | 10.2% | ||
| Q1 24 | 14.8% | 7.0% |
| Q4 25 | 11.1% | 6.9% | ||
| Q3 25 | 11.7% | 4.9% | ||
| Q2 25 | 4.0% | 3.2% | ||
| Q1 25 | 8.0% | -3.0% | ||
| Q4 24 | -5.4% | -2.1% | ||
| Q3 24 | -16.3% | 4.1% | ||
| Q2 24 | -1.7% | 4.8% | ||
| Q1 24 | 13.2% | 2.6% |
| Q4 25 | $1.14 | $1.44 | ||
| Q3 25 | $1.13 | $1.17 | ||
| Q2 25 | $0.36 | $0.81 | ||
| Q1 25 | $0.69 | $-0.68 | ||
| Q4 24 | $-0.45 | $-0.47 | ||
| Q3 24 | $-1.27 | $1.09 | ||
| Q2 24 | $-0.14 | $1.25 | ||
| Q1 24 | $0.82 | $0.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | — |
| Total DebtLower is stronger | — | $928.3M |
| Stockholders' EquityBook value | $540.7M | $574.0M |
| Total Assets | $1.4B | $1.9B |
| Debt / EquityLower = less leverage | — | 1.62× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | — | ||
| Q3 25 | $262.6M | — | ||
| Q2 25 | $217.8M | — | ||
| Q1 25 | $149.8M | — | ||
| Q4 24 | $144.9M | — | ||
| Q3 24 | $145.0M | — | ||
| Q2 24 | $240.1M | — | ||
| Q1 24 | $228.6M | — |
| Q4 25 | — | $928.3M | ||
| Q3 25 | — | $932.9M | ||
| Q2 25 | — | $977.5M | ||
| Q1 25 | — | $989.0M | ||
| Q4 24 | — | $939.5M | ||
| Q3 24 | — | $989.4M | ||
| Q2 24 | — | $1.0B | ||
| Q1 24 | — | $877.6M |
| Q4 25 | $540.7M | $574.0M | ||
| Q3 25 | $505.8M | $545.6M | ||
| Q2 25 | $436.8M | $526.8M | ||
| Q1 25 | $418.6M | $498.0M | ||
| Q4 24 | $403.7M | $488.7M | ||
| Q3 24 | $405.9M | $532.3M | ||
| Q2 24 | $455.8M | $509.2M | ||
| Q1 24 | $452.0M | $505.8M |
| Q4 25 | $1.4B | $1.9B | ||
| Q3 25 | $1.4B | $1.9B | ||
| Q2 25 | $1.3B | $1.9B | ||
| Q1 25 | $1.3B | $1.9B | ||
| Q4 24 | $1.3B | $1.9B | ||
| Q3 24 | $1.3B | $2.0B | ||
| Q2 24 | $920.8M | $1.9B | ||
| Q1 24 | $914.5M | $1.8B |
| Q4 25 | — | 1.62× | ||
| Q3 25 | — | 1.71× | ||
| Q2 25 | — | 1.86× | ||
| Q1 25 | — | 1.99× | ||
| Q4 24 | — | 1.92× | ||
| Q3 24 | — | 1.86× | ||
| Q2 24 | — | 1.97× | ||
| Q1 24 | — | 1.74× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $45.1M |
| Free Cash FlowOCF − Capex | $29.1M | $28.5M |
| FCF MarginFCF / Revenue | 11.8% | 6.6% |
| Capex IntensityCapex / Revenue | 0.5% | 3.8% |
| Cash ConversionOCF / Net Profit | 1.10× | 1.52× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $67.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $45.1M | ||
| Q3 25 | $44.1M | $49.6M | ||
| Q2 25 | $75.8M | $50.5M | ||
| Q1 25 | $35.0M | $-22.7M | ||
| Q4 24 | $15.9M | $74.7M | ||
| Q3 24 | $12.5M | $29.8M | ||
| Q2 24 | $17.4M | $27.2M | ||
| Q1 24 | $18.3M | $-12.3M |
| Q4 25 | $29.1M | $28.5M | ||
| Q3 25 | $38.0M | $37.6M | ||
| Q2 25 | $71.8M | $38.4M | ||
| Q1 25 | $32.5M | $-37.0M | ||
| Q4 24 | $13.5M | $56.1M | ||
| Q3 24 | $7.7M | $14.4M | ||
| Q2 24 | $13.0M | $10.1M | ||
| Q1 24 | $13.7M | $-38.6M |
| Q4 25 | 11.8% | 6.6% | ||
| Q3 25 | 16.7% | 7.7% | ||
| Q2 25 | 34.0% | 7.6% | ||
| Q1 25 | 16.5% | -8.1% | ||
| Q4 24 | 7.1% | 11.8% | ||
| Q3 24 | 5.2% | 2.6% | ||
| Q2 24 | 9.4% | 1.8% | ||
| Q1 24 | 10.0% | -7.8% |
| Q4 25 | 0.5% | 3.8% | ||
| Q3 25 | 2.7% | 2.5% | ||
| Q2 25 | 1.9% | 2.4% | ||
| Q1 25 | 1.3% | 3.1% | ||
| Q4 24 | 1.3% | 3.9% | ||
| Q3 24 | 3.2% | 2.8% | ||
| Q2 24 | 3.2% | 3.0% | ||
| Q1 24 | 3.3% | 5.3% |
| Q4 25 | 1.10× | 1.52× | ||
| Q3 25 | 1.66× | 2.08× | ||
| Q2 25 | 8.87× | 3.08× | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.31× | ||
| Q2 24 | — | 1.01× | ||
| Q1 24 | 1.00× | -0.95× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
KOP
| Other | $127.8M | 30% |
| Railroad Treated Products | $119.0M | 28% |
| Utility Poles | $79.8M | 18% |
| Pitch And Related Products | $74.1M | 17% |
| Carbon Black Feedstock And Distillates | $14.4M | 3% |
| Railroad Infrastructure Products And Services | $9.9M | 2% |
| Phthalic Anhydride Naphthalene And Other Chemicals | $7.7M | 2% |
